Skip to main content
. Author manuscript; available in PMC: 2017 Nov 22.
Published in final edited form as: Nat Genet. 2014 Mar 23;46(5):424–426. doi: 10.1038/ng.2922

Figure 2. Analyses of the splice-site mutation in case 102.

Figure 2

(a) Immunoblotting with antibody to the N terminus of SMARCA4. A high-grade serous ovarian cancer cell line (PEO4) and frozen tumor samples from two individuals with high-grade serous ovarian cancer (HGOC) were used as positive controls and retain protein expression. Protein extracted from H1299 non-small-cell lung cancer cells, deficient in SMARCA4, served as a negative control (Supplementary Fig. 6). Protein extracted from SCCOHT cases 101 and 102, both with donor-site splice-site mutations, show loss of SMARCA4 protein expression. (b) Loss of protein expression in archival tissue stained with a polyclonal antibody to SMARCA4. Note the intense staining of blood vessels and stromal cell nuclei as internal controls. Scale bar, 10 μm.